Impact on Radiotherapy

Tumor Microenvironment

Volumn , Issue , 2010, Pages 353-376

  Horsman, Michael R ^a   Overgaard, Jens ^a   Siemann, Dietmar W ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cancer stem cell role in tumorigenesis and therapy; Cell surviving fraction, function of radiation dose administered under normal aerated conditions or under hypoxia; Functional vascular supply, for growth and development of solid tumors; Hypoxia effect, on radiation response and tumor oxygenation; Hypoxia reduction and oxygen delivery increase; Measurement of oxygen partial pressure (pO2) distributions with polarographic electrodes; Radiation, administered under normal air breathing conditions or when tumors are clamped; Radiotherapy impact; Tumor hypoxia influence on radiation therapy; Tumour vasculature and microenvironment

Indexed keywords

EID: 84886028683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470669891.ch16     Document Type: Chapter

References (139)

1. Adams, G.E. and Cooke, M.S. (1969) Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. International Journal of Radiation Biology, 15, 457-471.
2. Adams, G.E., Flockhart, I.R., Smithen, C.E. et al. (1976) Electron-affinic sensitization VII: A correlation between structures, one-electron reduction potentials and efficiencies of some nitroimidazoles as hypoxic cell radiosensitizers. Radiation Research, 67, 9-20.
3. Airley, R.E., Loncaster, J., Raleigh, J. et al. (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. International Journal of Cancer, 104, 85-91.
4. Asquith, J.C., Watts, M.E., Patel, K. et al. (1974) Electron-affinic sensitization V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiation Research, 60, 108-118.
5. Baumann, M., Krause, M., and Hill, R. (2008) Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 8, 545-554.
6. Begg, A.C., Janssen, H., Sprong, D. et al. (2001) Hypoxia and perfusion measurements in human tumours: initial experience with pimonidazole and IUdR. Acta Oncologica, 40, 924-928.
7. Bergers, G. and Benjamin, L.E. (2003) Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3, 401-410.
8. Bergsjø, P. and Kolstad, P. (1968) Clinical trial with atmospheric oxygen breathing during radiotherapy of cancer of the cervix. Scandinavian Journal of Clinical Laboratory Investigations, 106, 167-171.
9. Brem, S., Brem, H., Folkman, J. et al. (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Research, 36, 2807-2812.
10. Brizel, D.M., Sibley, G.S., Prosnitz, L.R. et al. (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology Biology Physics, 38, 285-289.
11. Brown, J.M. (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. British Journal of Radiology, 52, 650-656.
12. 2-polarography, and fluorescentmicroscopy. International Journal of Radiation Oncology Biology Physics, 70, 1202-1212.
13. Bussink, J., Kaanders, J.H.A.M., and van der Kogel, A.J. (2003) Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiotherapy and Oncology, 67, 3-15.
14. Chaplin,D.J., Horsman,M.R., and Aoki,D.S. (1991) Nicotinamide, fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. British Journal of Cancer, 63, 109-113.
15. Chaplin, D.J., Horsman,M.R., and Siemann, D.W. (1993) Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. British Journal of Cancer, 68, 269-273.
16. Chaplin, D.J., Olive, P.L., and Durand, R.E. (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Research, 47, 597-601.
17. Chaplin, D.J. and Trotter, M.J. (1991) Chemical modifiers of tumor blood flow, in Tumor Blood Supply and Metabolic Microenvironment (eds P. Vaupel and R.K. Jain), Gustav Fischer Verlag, Stuttgart, New York, pp. 65-85.
18. Churchill-Davidson, I. (1968) The oxygen effect in radiotherapy: historical review. Frontiers of Radiation Therapeutic Oncology, 1, 1-15.
19. Denekamp, J. and Hobson, B. (1982) Endothelial-cell proliferation in experimental tumours. British Journal of Cancer, 46, 711-720.
20. Dische, S. (1979) Hyperbaric oxygen: the medical research council trials and their clinical significance. British Journal of Radiology, 51, 888-894.
21. Dische, S. (1985) Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiotherapy and Oncology, 3, 97-115.
22. Dische, S., Anderson, P.J., Sealy, R. et al. (1983) Carcinoma of the cervix: anaemia, radiotherapy and hyperbaric oxygen. British Journal of Radiology, 56, 251-255.
23. Dische, S., Machin, D., and Chassagne, D. (1993) A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiotherapy and Oncology, 26, 93-103.
24. Dobrowsky, W., Huigol, N.G., Jayatilake, R.S. et al. (2007) AK-2123 (sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomized trial. Radiotherapy and Oncology, 82, 24-29.
25. Dobrowsky, W., Naude, J., Dobrowsky, E. et al. (1995) Mitomycin C (MMC) and unconventional fractionation (V-CHART) in advanced head and neck cancer. Acta Oncologica, 34, 270-272.
26. Durand, R.E. and Sham, E. (1998) The lifetime of hypoxic tumor cells. International Journal of Radiation Oncology Biology Physics, 42, 711-715.
27. Du Sault, L.A. (1963) The effect of oxygen on the response of spontaneous tumours in mice to radiotherapy. British Journal of Radiology, 36, 749-754.
28. Eschwége, F., Sancho-Garnier, H., Chassagne, D. et al. (1997) Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. International Journal of Radiation Oncology Biology Physics, 39, 275-281.
29. Evans, J.C. and Bergsjø, P. (1965) The influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology, 84, 709-717.
30. Folkman, J. (1986) How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Research, 46, 467-473.
31. Gatenby, R.A., Kessler, H.B., Rosenblum, J.S. et al. (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. International Journal of Radiation Oncology Biology Physics, 14, 831-838.
32. Gerweck, L.E., Gillette, E.L., and Dewey, W.C. (1974) Killing of chinese hamster cells in vitro by heating under hypoxic or aerobic conditions. European Journal of Cancer, 10, 691-693.
33. Gerweck, L.E., Nygaard, T.G., and Burlett, M. (1979) Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Research, 39, 966-972.
34. Grau, C., Agarwal, J.P., Jabeen, K. et al. (2003) Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomized trial. Radiotherapy and Oncology, 67, 17-27.
35. Grau, C., Horsman, M.R., and Overgaard, J. (1992) Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen and carbogen breathing. International Journal of Radiation Oncology Biology Physics, 22, 415-419.
36. Grau, C. and Overgaard, J. (1998) Significance of haemoglobin cincentration for treatment outcome, in Medical Radiology: Blood Perfusion and Microenvironment of Human Tumours (eds M. Molls and P. Vaupel), Springer-Verlag, Heidelberg, pp. 101-112.
37. Gray, L.H., Conger, A.D., Ebert, M. et al. (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. British Journal of Radiology, 26, 638-648.
38. Grogan, M., Thomas, G.M., Melamed, I. et al. (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer, 86, 1528-1536.
39. Haffty, B.G., Son, Y.H., Sasaki, C.T. et al. (1993) Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. International Journal of Radiation Oncology Biology Physics, 27, 241-250.
40. Haffty, B.G., Wilson, L.D., Son, Y.H. et al. (2005) Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. International Journal of Radiation Oncology Biology Physics, 61, 5-6.
41. Hahn, G.M. (1974) Metabolic aspects of the role of hyperthermia in mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Research, 34, 3117-3123.
42. Hahn, G.M. (1982) Hyperthermia and Cancer, Plenum Press, New York.
43. Hahnfeldt, P., Panigrahy, D., Folkman, J., and Hlatky, L. (1999) Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Research, 59, 4770-4775.
44. Hall, E.J. (1994) Radiobiology for the Radiobiologist, 4th edn, JB Lippincott, Philadelphia.
45. Hall, E.J. and Roizin-Towle, L. (1975) Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology, 117, 453-457.
46. Helmlinger, G., Yuan, F., Dellian, M., and Jain, R.K. (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature Medicine, 3, 177-182.
47. Henk, J.M., Kunkler, P.B., and Smith, C.W. (1977) Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet, 2 (8029), 101-103.
48. Henk, J.M. and Smith, C.W. (1977) Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet, 2 (8029), 104-105.
49. Henke, M., Laszig, R., Rube, C. et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebocontrolled trial. Lancet, 362, 1255-1260.
50. Hill, R.P., Marie-Egyptienne, D.T., and Hedley, D.W. (2009) Cancer stem cells, hypoxia and metastasis. Seminars in Radiation Oncology, 19, 106-111.
51. Hirst, D.G. and Wood, P.J. (1991) Could manipulation of the binding affinity of haemoglobin for oxygen be used clinically to sensitize tumours to radiation? Radiotherapy and Oncology, 20, 53-57.
52. Hoeckel, M., Knoop, C., Schlenger, K. et al. (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45-50.
53. Horsman, M.R. (1993) Hypoxia in tumours: its relevance, identification and modification, in Current Topics in Clinical Radiobiology of Tumours (ed. H. Beck-Bornholdt), Springer- Verlag, Berlin, pp. 99-112.
54. Horsman, M.R. (1995) Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. Acta Oncologica, 34, 571-587.
55. Horsman, M.R. (1998) Measurement of tumor oxygenation. International Journal of Radiation Oncology Biology Physics, 42, 701-704.
56. Horsman, M.R. and Overgaard, J. (2007) Hyperthermia: a potent enhancer of radiotherapy. Clinical Oncology, 19, 418-426.
57. Horsman, M.R. and Siemann, D.W. (2006) Pathophysiological effects of vascular targeting agents and the implications for combination therapies. Cancer Research, 66, 11520-11539.
58. Horsman, M.R., Chaplin, D.J., and Overgaard, J. (1990) Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Research, 50, 7430-7436.
59. Horsman, M.R., Khalil, A.A., Nordsmark, M. et al. (1993) Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. Radiotherapy and Oncology, 28, 69-71.
60. Horsman,M.R., Khalil, A.A., Siemann, D.W. et al. (1994a) Relationship between radiobiological hypoxia in tumours and electrode measurements of tumour oxygenation. International Journal of Radiation Oncology Biology Physics, 29, 439-442.
61. Horsman, M.R., Nordsmark, M., Khalil, A.A. et al. (1994b) Reducing chronic and acute hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncology, 33, 371-376.
62. Hoskin, P.J., Robinson, M., Slevin, N. et al. (2009a) Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. Journal of Clinical Oncology, 27, 5751-5756.
63. Hoskin, P.J., Rojas, A., and Saunders, M.I. (2009b) Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: Mature results of a phase II nonrandomized study. International Journal of Radiation Oncology Biology Physics, 73, 1425-1431.
64. Hui, E.P.,Chan, A.T.C., Pezzella, F. et al. (2002) Coexpression of hypoxia-inducible factors 1a and 2 a, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research, 8, 2595-2604.
65. Jain, R.K. (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine, 7, 987-989.
66. Janssen, H.L., Haustermans, K.M., Sprong, D. et al. (2002) HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. International Journal of Radiation Oncology Biology Physics, 54, 1537-1549.
67. Kaanders, J.H., Bussink, J., and van der Kogel, A.J. (2002a) ARCON: a novel biology-based approach in radiotherapy. Lancet Oncology, 3, 728-737.
68. Kaanders, J.H.A.M., Pop, L.A.M., Marres, H.A.M. et al. (2002b) ARCON: experience in 215 patients with advanced head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 52, 769-778.
69. Kampinga, H.H. and Dikomey, E. (2001) Hyperthermic radiosensitization: mode of action and clinical relevance. International Journal of Radiation Biology, 77, 399-408.
70. Kennedy, K.A., Rockwell, S., and Sartorelli, A.C. (1980) Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Research, 40, 2356-2360.
71. Kimura, H., Braun, R.D., Ong, E.T. et al. (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Research, 56, 5522-5528.
72. Kjellen, E., Joiner, M.C., Collier, J.M. et al. (1991) A therapuetic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiotherapy and Oncology, 22, 81-91.
73. Kolstad, P. (1968) Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scandinavian Journal of Clinical Laboratory Investigation, 106, 145-157.
74. Krohn, K.A., Link, J.M., and Mason, R.P. (2008) Molecular imaging of hypoxia. Journal of Nuclear Medicine, 49 (Suppl. 2), 129S-148S.
75. Lauk, S., Skates, S., Goodman, M., and Suit, H.D. (1989) Morphometric study of the vascularity of oral squamous cell carcinomas and its relation to outcome of radiation therapy. European Journal of Cancer Clinical Oncology, 25, 1431-1440.
76. Lavey, R.S. andDempsey,W.H. (1993) Erythropoietin increases hemoglobin in cancer patients during radiotherapy. International Journal of Radiation Oncology Biology Physics, 27, 1147-1152.
77. Le, Q.T., Sutpin, P.D., Raychaudhuri, S. et al. (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clinical Cancer Research, 9, 59-67.
78. Lee, D.J., Cosmatos, D., Marcial, V.A. et al. (1995) Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole (SR-2508) with radiotherapy alone for locally advanced head and neck carcinomas. International Journal of Radiation Oncology Biology Physics, 32, 567-576.
79. Li, G.C. and Kal, H.B. (1977) Effect of hyperthermia on the radiation response of two mammalian cell lines. European Journal of Cancer, 13, 65-69.
80. Machtay, M., Pajak, T., Suntharalingam, M. et al. (2007) Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). International Journal of Radiation Oncology Biology Physics, 69, 1008-1017.
81. McKeown, S.R., Cowen, R.L., Williams, K.J. (2007) Bioreductive drugs: from concept to clinic. Clinical Oncology, 19, 427-442.
82. Mendenhall, W.M.,Morris, C.G., Amdur, R.J. et al. (2005) Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective randomized trial. Cancer, 104, 333-337.
83. Moulder, J.E. and Rockwell, S. (1984) Hypoxic fractions of solid tumour. International Journal of Radiation Oncology Biology Physics, 10, 695-712.
84. Müller, C. (1910) Eine neue Behandlungsmethode bö sartiger Geschwü lste. Munchener Medizinische Wochenschrift, 28, 1490-1493.
85. Murata, R. and Horsman, M.R. (2004) Tumor specific enhancement of thermotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Hyperthermia, 20, 393-404.
86. Murata, R., Siemann, D.W., Overgaard, J., and Horsman, M.R. (2001a) Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiotherapy and Oncology, 60, 155-161.
87. Murata, R., Siemann, D.W., Overgaard, J., and Horsman, M.R. (2001b) Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone- 4-acetic acid. Radiation Research, 156, 503-509.
88. Murata, R., Tsujitani, M., and Horsman, M.R. (2008) Enhanced local tumour control after single and fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiotherapy and Oncology, 87, 331-338.
89. Nielsen, O.S. (1981) Effect of fractionated hyperthermia on hypoxic cells in vitro. International Journal of Radiation Biology, 39, 73-80.
90. Nordsmark, M., Overgaard, M., and Overgaard, J. (1996) Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiotherapy and Oncology, 41, 31-39.
91. Nordsmark, M., Bentzen, S.M., Rudat, V. et al. (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An internationalmulti-center study. Radiotherapy and Oncology, 77, 18-24.
92. Nordsmark, M., Eriksen, J.G., Gebski, V. et al. (2007) Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiotherapy and Oncology, 83, 389-397.
93. Olive, P.L. and Aquino-Parsons, C. (2004) Measurement of tumor hypoxia using single cell methods. Seminars in Radiation Oncology, 14, 241-248.
94. Overgaard, J. (1989) Sensitization of hypoxic tumour cells-clinical experience. International Journal of Radiation Biology, 56, 801-811.
95. Overgaard, J. (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncology Research, 6, 509-518.
96. Overgaard, J. and Bichel, P. (1977) The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiology, 123, 511-514.
97. Overgaard, J. and Nielsen, O.S. (1980) The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Annuals of the NewYork Academy of Science, 335, 254-280.
98. Overgaard, J., Hansen, H.S., Andersen, A.P. et al. (1989) Misonidazole combined with splitcourse radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx: report from the DAHANCA 2 study. International Journal of Radiation Oncology Biology Physics, 16, 1065-1068.
99. Overgaard, J., Sand Hansen, H., Overgaard, M. et al. (1998) A randomised double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiotherapy and Oncology, 46, 135-146.
100. Overgaard, J., Eriksen, J.G., Nordsmark, M. et al. (2005) Plasma osteopontin predicts hypoxia and response to the hypoxic sensitizer nimoprazole in radiotherapy of head and neck cancer. Results from the randomized DAHANCA 5 trial. Lancet Oncology, 6, 757-764.
101. Overgaard, J., Hoff, C., Sand Hansen, H. et al. (2007) Randomized study of the importance of novel erythropoiesis stimulating protein (aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)-the Danish Head and Neck Cancer group DAHANCA 10 randomized trial. European Journal of Cancer, 5, 7.
102. Petersen, C., Zips, D., Krause, M. et al. (2001) Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. International Journal of Radiation Oncology Biology Physics, 51, 483-493.
103. Piert, M., Machulla, H.J., Picchio, M. et al. (2005) Hypoxia-specific tumor imaging with 18F-Fluoroazomycin arabinoside. Journal of Nuclear Medicine, 46, 106-113.
104. Powell, M.E., Hill, S.A., Saunders, M.I. et al. (1997) Human tumor blood flow is enhanced by nicotinamide and carbogen breathing. Cancer Research, 57, 5261-5264.
105. Power, J.A. and Harris, J.W. (1977) Response of extremely hypoxic cells to hyperthermia: survival and oxygen enhancement ratios. Radiology, 123, 767-770.
106. Raleigh, J.A., Dewhirst, M.W., and Thrall, D.E. (1996) Measuring tumor hypoxia. Seminars in Radiation Oncology, 6, 37-45.
107. Rasey, J.S., Koh, W.J., Evans, M.L. et al. (1996) Quantifying regional hypoxia in human tumors with positron emission tomography of 18F-fluoromisonidazole: a pretherapy study of 37 patients. International Journal of Radiation Oncology Biology Physics, 36, 417-428.
108. Révész, L., Siracka, E., Siracky, J. et al. (1989) Variation of vascular density within and between tumors of the uterine cervix and its predictive value for radiotherapy. International Journal of Radiation Oncology Biology Physics, 16, 1161-1163.
109. Rockwell, S. (1985) Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor. International Journal of Radiation Oncology Biology Physics, 11, 97-103.
110. Rojas, A. (1991) Radiosensitization with normobaric oxygen and carbogen. Radiotherapy and Oncology, 20 (Suppl. 1), 65-70.
111. Roti Roti, J.L. (2004) Introduction: radiosensitization by hyperthermia. International Journal of Hyperthermia, 20, 109-114.
112. Rubin, P., Hanley, J., Keys, H.M. et al. (1979) Carbogen breathing during radiation therapy. The RTOG study. International Journal of Radiation Oncology Biology Physics, 5, 1963-1970.
113. Sapareto, S.A., Raaphorst, P., and Dewey, W.C. (1979) Cell killing and the sequencing of hyperthermia and radiation. International Journal of Radiation Oncology Biology Physics, 5, 343-347.
114. Schwarz, G. (1909) Über Desensibiliserung gegen Röntgen-und Radiumstrahlen.Munchener Medizinische Wochenschrift, 24, 1-2.
115. Seddon, B.M., Payne, G.S., Simmons, L. et al. (2003) A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clinical Cancer Research, 9, 5101-5112.
116. Siemann, D.W. and Macler, L.M. (1986) Tumor radiosensitization through reductions in hemoglobin affinity. International Journal of Radiation Oncology Biology Physics, 12, 1295-1297.
117. Siemann, D.W. and Rojiani, A.M. (2002) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation Oncology Biology Physics, 53, 164-171.
118. Siemann, D.W., Bibby,M.C., Dark, G. et al. (2005) Differentiation and definition of vasculartargeted therapies. Clinical Cancer Research, 11, 416-420.
119. Siemann, D.W., Chaplin, D.J., and Horsman, M.R. (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, 2491-2499.
120. Siemann, D.W., Hill, R.P., and Bush, R.S. (1977) The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2; 95% O2) on the in vivo radiation response of a murine sarcoma. International Journal of Radiation Oncology Biology Physics, 2, 903-911.
121. Stoeltzing, O. and Ellis, L.M. (2006) The role of microvasculature in metastasis formation, in Vascular-targeted Therapies in Oncology (ed. D.W. Siemann), John Wiley & Sons, Ltd, Chichester, pp. 31-62.
122. Stratford, I.J. and Stephens,M.A. (1989) The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by theMTT assay. International Journal of Radiation Oncology Biology Physics, 16, 973-976.
123. Stratford, I.J., O'Neill, P., Sheldon, P.W. et al. (1986) RSU 1069, a nitroimidazole containing an aziridine group: bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochemical Pharmacology, 35, 105-109.
124. Stuben, G., Pottgen, C., Knuhmann, K. et al. (2003) Erythropoietin restores the anemiainduced reduction in radiosensitivity of experimental human tumors in nude mice. International Journal of Radiation Oncology Biology Physics, 55, 1358-1362.
125. Suit, H.D. and Gerweck, L.E. (1979) Potential for hyperthermia and radiation therapy. Cancer Research, 39, 2290-2298.
126. Suit, H.D., Marshall, N., and Woerner, D. (1972) Oxygen, oxygen plus carbondioxide, and radiation therapy of a mouse mammary carcinoma. Cancer, 30, 1154-1158.
127. Tannock, I.F. (1968) The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour. British Journal of Cancer, 22, 258-273.
128. Thews, O., Koenig, R., Kelleher, D.K. et al. (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. British Journal of Cancer, 78, 752-756.
129. Thomas, G.M. (2002) Raising hemoglobin: an opportunity for increasing survival? Oncology, 63, 19-28.
130. Thomlinson, R.H. and Gray, L.H. (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539-549.
131. Urtasun, R., Band, P., Chapman, J.D. et al. (1976) Radiation and high-dose metronidazole in supratentorial glioblastomas. New England Journal of Medicine, 294, 1364-1367.
132. Urtasun, R.C., Parliament, M.B., McEwan, A.J. et al. (1996) Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. British Journal of Cancer, 74, S209-S212.
133. Vaupel, P. (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology, 14, 198-206.
134. Vaupel, P., Kallinowski, F., and Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic micro-environment of human tumors: a review. Cancer Research, 49, 6449-6465.
135. Watson, E.R., Halnan, K.E., Dische, S. et al. (1978) Hyperbaric oxygen and radiotherapy: a medical research council trial in carcinoma of the cervix. British Journal of Radiology, 51, 879-887.
136. Weissberg, J.B., Son, Y.H., Papac, R.J. et al. (1989) Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. International Journal of Radiation Oncology Biology Physics, 17, 3-9.
137. Wilson, W.W., Li, A.E., Cowan, D., and Siim, B.G. (1998) Enhancement of tumor radiation response by the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Radiation Oncology Biology Physics, 42, 905-908.
138. Yaromina, A., Zips, D., Thames, H.D. et al. (2006) Pimonidazole labeling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiotherapy and Oncology, 81, 122-129.
139. Zeman, E.M., Hirst, V.K., Lemmon, M.J., and Brown, J.M. (1988) Enhancement of radiationinduced tumor cell killing by the hypoxic cell toxin SR 4233. Radiotherapy andOncology, 12, 209-218.